Publications
Detailed Information
Identification of YH18421, a novel GPR119 agonist for the treatment of type 2 diabetes : 제2형 당뇨병 치료를 위한 새로운 GPR119 작용제로써 YH18421 동정
Cited 0 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Advisor
- 김규원
- Major
- 약학대학 약학과
- Issue Date
- 2017-08
- Publisher
- 서울대학교 대학원
- Keywords
- YH18421 ; GPR119 ; DPP-IV inhibitor ; GLP-1 ; Insulin ; Type 2 diabetes
- Description
- 학위논문 (박사)-- 서울대학교 대학원 약학대학 약학과, 2017. 8. 김규원.
- Abstract
- G-protein-coupled receptor 119 (GPR119) represents a promising target for the treatment of type 2 diabetes as it can increase both GLP-1 secretion from intestinal L cells and glucose-stimulated insulin secretion (GSIS) from pancreatic cells. Due to these dual mechanism of action, the development of small molecule GPR119 agonists have received much interest for the treatment of type 2 diabetes. Here, YH18421, a novel small-molecule GPR119 agonist was identified and its therapeutic potential was evaluated. YH18421 specifically activated human GPR119 with high potency and potentiated GLP-1 secretion and GSIS in vitro cell based systems. In normal mice, single oral administration of YH18421 improved glucose tolerance. Combined treatment of YH18421 and the DPP-IV inhibitor augmented both plasma active GLP-1 levels and glycemic control. In diet induced obese (DIO) mice model, glucose lowering effect of YH18421 was maintained after 4 weeks of repeat dosing and YH18421 acted additively with DPP-IV inhibitor. YH18421 also inhibited weight gain during 4 weeks of administration in DIO mice. These results demonstrate that YH18421 is capable of delivering sustained glucose control and preventing weight gain and suggest that YH18421 alone or in combination with a DPP-IV inhibitor, represents a new type of an oral GLP-1 based therapy for the treatment of type 2 diabetes
- Language
- English
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.